Conjugates for targeted delivery that are based on low-molecular-mass prostate specific membrane antigen (PSMA) inhibitors are widely used and developed because of the deficiencies of existing methods for treating and diagnosing prostate cancer. The major classes of low-molecular-mass PSMA inhibitors, drug classes, and their mechanisms of action are discussed. Therapeutic conjugates for targeted delivery that are based on them are analyzed. Structural features of the linker that affect the biological activity and selectivity are identified.
This is a preview of subscription content, access via your institution.














References
Cancer Facts & Figures, American Cancer Society, Inc., No. 500817, 2017.
M. J. Barry, “Clinical practice,” N. Engl. J. Med., 344(18), 1373 – 1377 (2001); DOI: https://doi.org/10.1056/NEJM200105033441806.
B. S. Slusher, Handbook of Proteolytic Enzymes, Vol. 2, pp. 1620 – 1627, 2013; DOI https://doi.org/10.1016/j.bmc.2018.11.022.
V. P. Chekhonin, M. E. Grigor’ev, and Yu. A. Zharkov, Vopr. Med. Khim., 48, 31 – 72 (2002); PubMed: 12068496.
L. S. Grauer, K. D. Lawler, and J. Marignac, Cancer Res., 58(21), 4787 – 4789 (1998); PMID: 98009977; DOI: Published November 1998.
A. Ghosh and W. D. W. Heston, J. Cell. Biochem., 91(3), 528 – 539 (2004); DOI: https://doi.org/10.1002/jcb.10661.
A. E. Machulkin, Y. A. Ivanenkov, A. V. Aladinskaya, et al., J. Drug Targeting, 24(8), 679 – 693 (2016); DOI: https://doi.org/10.3109/1061186X.2016.1154564.
N. Subasinghe, M. Schulte, M. Y.-M. Chan, et al., J. Med. Chem., 33(10), 2734 – 2744 (1990); DOI: https://doi.org/10.1021/jm00172a009.
P. F. Jackson, D. C. Cole, B. S. Slusher, et al., J. Med. Chem., 39, 619 – 622 (1996); DOI: https://doi.org/10.1021/jm950801q.
C. Barinka, C. Rojas, and B. Slusher, Curr. Med. Chem., 19, 856 – 870 (2012); DOI: https://doi.org/10.2174/092986712799034888.
A. P. Kozikowski, F. Nan, P. Conti, et al., J. Med. Chem., 44(3), 298 – 301 (2001); DOI: https://doi.org/10.1021/jm000406m.
S. A. Kularatne, Z. Zhou, J. Yang, et al., Mol. Pharmaceutics, 6(3), 790 – 800 (2009); DOI: https://doi.org/10.1021/mp9000712.
K. P. Maresca, S. M. Hillier, F. J. Femia, et al., J. Med. Chem., 52, 347 – 357 (2009); DOI: https://doi.org/10.1021/jm800994j.
J. Tykvart, J. Schimer, J. Barinkova, et al., Bioorg. Med. Chem., 22, 4099 – 4108 (2014); DOI: https://doi.org/10.1016/j.bmc.2014.05.061.
T. H. Pillow, J. D. Sadowsky, D. Zhang, et al., Chem. Sci., 8, 366 – 370 (2017); DOI: https://doi.org/10.1039/C6SC01831A.
T. C. Johnstone, K. Suntharalingam, S. J. Lippard, et al., Chem. Rev., 116, 3436 – 3486 (2016); DOI: https://doi.org/10.1021/acs.chemrev.5b00597.
U. Basu, B. Banik, R. Wen, et al., Dalton Trans., 45, 12992 – 13004 (2016); DOI: https://doi.org/10.1039/C6DT01738J.
E. Borre, G. Dahm, G. Guichard, et al., New J. Chem., 40, 3164 – 3171 (2016); DOI: https://doi.org/10.1039/C5NJ03104D.
F. M. Veronese, O. Schiavon, G. Pasut, et al., Bioconjugate Chem., 16, 775 – 784 (2005); DOI: https://doi.org/10.1021/bc040241m.
O. V. Zhukova, T. F. Sergeeva, and A. I. Gavrina, Khim.-farm. Zh., 52(6), 38 – 43 (2018); Pharm. Chem. J., 52(6), 539 – 544 (2018); DOI: https://doi.org/10.30906/0023-1134-2018-52-6-38-43.
L. Wong, M. Kavallarisc, V. Bulmus, et al., Polym. Chem., 2, 385 – 393 (2011); DOI: https://doi.org/10.1039/C0PY00256A.
T. Jiang, Y. M. Li, and Y. Lv, Colloids Surf., B, 111, 542 – 548 (2013); DOI: https://doi.org/10.1016/j.colsurfb.2013.06.054.
B. M. Mueller, W. A. Wrasidlo, R. A. Reisfeld, et al., Bioconjugate Chem., 7, 325 – 330 (1990); DOI: https://doi.org/10.1021/bc00005a005.
S. Jayaprakash, X. Wang, W. D. Heston, et al., ChemMed-Chem., 1, 299 – 302 (2006); DOI: https://doi.org/10.1002/cmdc.200500044.
G. M. Dubowchik, R. A. Firestone, L. Padilla, et al., Bioconjugate Chem., 13, 855 – 869 (2002); DOI: https://doi.org/10.1021/bc025536j.
G. R. Pettit, S. B. Singh, J. K. Srirangam, et al., J. Org. Chem., 59, 1796 – 1800 (1994); DOI: https://doi.org/10.1021/jo00086a034.
S. O. Doronina, B. E. Toki, M. Y. Torgov, et al., Nat. Biotechnol., 21(7), 778 – 784 (2003); DOI: https://doi.org/10.1038/nbt832.
V. A. DiPippo, H. M. Nguyen, L. G. Brown, et al., Wiley Online Library, 76(3), 325 – 334 (2016); DOI: https://doi.org/10.1002/pros.23124.
I. Ojima, O. Duclos, M. Zucco, et al., J. Med. Chem., 37, 2602 – 2608 (1994); DOI: https://doi.org/10.1021/jm00042a013.
N. M. Bhatia, P. K. Kulkarni, S. S. Ashtekar, et al., Pharm. Chem. J., 51(11), 1005 – 1013 (2018); DOI: https://doi.org/10.1007/s11094018-1730-8.
H. Kim, Y. Lee, I. H. Lee, et al., J. Controlled Release, 178, 118 – 124 (2014); DOI: https://doi.org/10.1016/j.jconrel.2014.01.015.
Z. H. Peng, M. Sima, M. E. Salama, et al., J. Drug Targeting, 21(10), 968 – 980 (2013); DOI: https://doi.org/10.3109/1061186X.2013.833207.
S. A. Kularatne, C. Venkatesh, H. K. R. Santhapuram, et al., J. Med. Chem., 53, 7767 – 7777 (2010); DOI: https://doi.org/10.1021/jm100729b.
M. J. Morris, N. J. Vogelzang, O. Saltor, et al., J. Clin. Oncol., 35(15), 5038 – 5038 (2017); DOI: https://doi.org/10.1200/JCO.2017.35.15suppl.5038.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 53, No. 4, pp. 10 – 19, April, 2019.
Rights and permissions
About this article
Cite this article
Uspenskaya, A.A., Machulkin, A.É., Mazhuga, A.G. et al. Conjugates of Prostate-Specific Membrane Antigen Ligands with Antitumor Drugs. Pharm Chem J 53, 288–297 (2019). https://doi.org/10.1007/s11094-019-01994-1
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11094-019-01994-1